Women with visceral metastases following breast cancer have a poorer prognosis than those with bony lesions ([@bib6]; [@bib3]). Although bone is the most frequently affected site after a primary breast cancer ([@bib2]), little is known regarding the organ-preferential metastasis after metachronous contralateral breast cancer (CBC).

Recently, we found that women who develop CBC within 5 years are at an increased risk of dying from breast cancer ([@bib8]). We therefore hypothesised that some CBCs, occurring early, indicate the presence of systemic disease and potentially a preference for visceral metastatic pathways. To elucidate these findings, we compared the patterns of metastasis in women diagnosed with CBC within and after 5 years with those in women with unilateral breast cancer (UBC).

Patients and Methods
====================

Patients
--------

We identified 8478 women treated for an invasive primary breast cancer at Guy\'s and St Thomas\' NHS Foundation Trust between 1975 and 2006. We used a 6-month interval to distinguish metachronous from synchronous CBC ([@bib5]).

We excluded: 5 women who underwent contralateral prophylactic mastectomy, 20 with synchronous CBC, 205 who contributed less than 6 months of follow-up, 22 with metastasis at the time of CBC diagnosis and 400 with metastasis at the time of initial diagnosis. To allow for equal time at risk of developing metastasis, we excluded 127 women lost to follow-up and 105 who developed distant metastasis within 6 months of the initial breast cancer, leaving 7594 eligible women, of whom 305 developed metachronous CBC.

Our outcome of interest was distant metastasis. Distant metastases were defined as any lesion located outside the breast tissue, mastectomy scar, ipsilateral axillary lymph nodes or ipsilateral supraclavicular lymph nodes. Sites of metastasis were grouped as: bone; visceral (lesions in thoracic or abdominal viscera); central nervous system; distant cutaneous; distant lymph nodes; multiple organs (metastases diagnosed at two or more sites within 6 months after the first distant metastasis); and unknown site. The study has the approval of the Guy\'s NHS Research Ethics Committee.

Statistical analysis
--------------------

Five-year cumulative incidence was calculated for each metastatic site. *P*-values were estimated using Gray\'s test. Incidence rate ratios (IRR) were computed via percentile bootstrap estimates. The probability curves for visceral or distant cutaneous metastases were estimated using competing risk regression using interval time to CBC as an explanatory variable in a linear model and in a nonlinear model.

Results
=======

[Figure 1](#fig1){ref-type="fig"} shows the 5-year cumulative incidence curves for each metastatic site. Lymph node involvement at the contralateral axilla was considered as a distant lymph node metastasis for women with UBC and a local recurrence for women with CBC, therefore no women with CBC were classified in this category.

The cumulative incidence of metastases for women diagnosed with CBC within 5 years rose steeply after diagnosis ([Figure 1](#fig1){ref-type="fig"}, panel B). Compared with women with UBC, visceral and cutaneous metastases occurred more often in women with CBC within 5 years as shown in panels A and B (*P*\<0.001 for both sites). The slope and the site-specific cumulative incidence curves were similar between women with UBC and women with CBC more than 5 years after the initial cancer ([Figure 1](#fig1){ref-type="fig"}, panels A and C).

Compared with women with UBC and women with CBC more than 5 years after the initial diagnosis, women with CBC within 5 years had higher IRRs for visceral and cutaneous metastasis than for bone metastasis (for example, IRR 2.1 and 1.5, respectively, compared with 1.3 and 0.16 for women with UBC; [Figure 1](#fig1){ref-type="fig"}, panels A, B and C).

Five-year cumulative incidence of metastases was lower in women with UBC who received tamoxifen for the initial tumour (24% *vs* 33%, *P*\<0.001). In women with CBC, tamoxifen treatment for the initial tumour was not associated with metastasis after CBC (54% *vs* 58% for women with CBC within 5 years and 26% *vs* 23% for women with CBC after 5 years, who received and did not receive tamoxifen, respectively). Metastatic occurrence in women with CBC with an initial cancer diagnosis after 1990 was lower than that of those diagnosed before 1990 but not statistically significantly different (45% *vs* 61%, *P*=0.07 for women with CBC within 5 years). Period of initial diagnosis was not associated with metastatic occurrence in women with CBC after more than 5 years.

[Figure 2](#fig2){ref-type="fig"} illustrates the probabilities of developing visceral or distant cutaneous metastasis after CBC against interval time to CBC. Under both assumptions of linearity and nonlinearity, the probability was high immediately after the CBC diagnosis and gradually decreased with a longer interval time.

Discussion
==========

Women diagnosed with CBC within 5 years more commonly presented with metastasis to visceral organs and distant cutaneous sites, compared with women with UBC. A steep increase in cumulative incidence curves for women with CBC within 5 years indicates a rapid disease progression. Women diagnosed with CBC more than 5 years after the initial breast cancer had patterns of metastatic spread similar to women with UBC.

The similar incidence and patterns of metastasis in women with UBC and those with CBC diagnosed after more than 5 years, suggests that the tumour biology of these tumours is similar. In contrast, the rapid occurrence of metastases among women diagnosed with CBC within 5 years of their primary cancer and the predilection for visceral and distant cutaneous metastasis supports our previous findings of poor prognosis among women diagnosed with CBC soon after the initial breast cancer ([@bib8], [@bib9]). We do not have access to detailed morphological data or molecular profiles of the two cancers, and therefore we cannot distinguish a new primary CBC from a metastatic lesion. Studies investigating the clonal relationship between primary breast cancer and CBC reported evidence of metastatic CBC, although this was rarer than a new primary CBC ([@bib4]; [@bib7]).

We limited the study to the first metastatic occurrence because any subsequent metastases may be underreported when patients reach palliative care. During the period of this study, metastatic sites were diagnosed primarily using different types of imaging and very occasionally histopathology. Information on metastasis was available in more than 90% of women dying from breast cancer. Owing to the possible underreporting of metastases, we separately reported on women who died of breast cancer without a record of metastasis. Site of metastasis was not reported in 1% of all women and in 5% of women diagnosed with CBC within 5 years.

Tamoxifen treatment reduces the risk of developing CBC ([@bib1]) but the treatment of the initial breast cancer was not associated with the incidence of metastasis after CBC. The trend for a lower incidence of metastases after 1990 may reflect the improvements in diagnosis and treatment.

Conclusion
==========

Our data indicate that a significant proportion of CBCs occurring shortly after the initial cancer may represent or indicate active systemic disease. Further experimental studies are warranted for verifying CBC\'s biological nature. The rapidly rising high incidence of visceral and cutaneous metastases in women with a short interval to CBC raises questions about clinical management of women in this situation.
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